Corporate Governance

Gregory B. Brown, M.D. has served as a member of the Company’s board of directors since March 2007. Dr. Brown is currently the Chief Executive Officer and member of the Board of Directors of Memgen, LLC, a private clinical-stage biotechnology company. He is a co-founder of HealthCare Royalty Partners, or HCRx, and is a member of that firm’s Senior Advisor Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led a health maintenance organization. Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a BA from Yale University, an M.D. from SUNY Upstate Medical Center and an MBA from Harvard University. Dr. Brown currently serves on the board of the following public pharmaceutical company: Lisata Therapeutics, Inc. (Nasdaq: LSTA) (formerly Caladrius Biosciences, Inc;. Nasdaq: CLBS).

Abigail “Abbey” L. Jenkins is an experienced biopharmaceutical executive and board director with more than 25 years of leadership across public and private biotech and pharmaceutical companies. She has a proven track record of building and leading organizations through strategic transformations—including growth, business reshaping, and the pursuit of strategic alternatives—along with commercialization and value creation, having successfully launched six products and raised more than $250 million in capital across her career. Ms. Jenkins is currently the CEO of a Stealth Mode Biotech developing novel therapies for patients with cancer. She previously served as President, Chief Executive Officer, and a member of the Board of Directors of Gamida Cell, Ltd. (NASDAQ: GMDA), a pioneer in cell therapies for patients with blood cancers. During her tenure, she led the company through the FDA approval and launch of Omisirge®, the first-ever allogeneic hematopoietic stem cell donor source approved in the United States. Prior to Gamida Cell, she was Chief Commercial and Business Officer at Lyndra Therapeutics, where she established and led global commercial, business development, corporate strategy, and portfolio management functions across multiple therapeutic areas. Earlier in her career, Ms. Jenkins served as Chief Commercial and Business Officer at Lyndra Therapeutics, Senior Vice President and Business Unit Head of Vaccines at Emergent BioSolutions (NYSE: EBS), as Chief Commercial Officer and U.S. Business Head at Aquinox Pharmaceuticals (NASDAQ: AQXP). She has also held senior commercial and business development roles at Relypsa, Actavis (now Teva Pharmaceuticals), MedImmune (now AstraZeneca), and Pfizer. Ms. Jenkins currently serves on the Board of Directors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) and previously served on the Board of Directors of XORTX Therapeutics, Inc. (NASDAQ: XRTX). She is also Chair of the Editorial Board of the Biotech CEO Sisterhood. She holds a Master of Science in Biotechnology and Biotechnology Business Enterprise from The Johns Hopkins University, a Bachelor of Arts in Psychology and Biology from Indiana University, and a Certificate of Achievement in General Management as a Kellogg Executive Scholar. In 2022, she was recognized as a PharmaVoice 100 honoree in the Disrupter category, honoring the industry’s most inspiring and impactful leaders. Our Board believes that Ms. Jenkins’ extensive experience in the commercialization of pharmaceutical products, her business development and corporate strategy expertise and her experience on the boards of public companies and in senior leadership roles across several biopharmaceutical companies qualifies her to serve on our Board of Directors.

Julie Krop, M.D. has served as a member of our Board since February 2021. Dr. Krop is currently the Chief Medical Officer of DiaMedica Therapeutics, Inc. (Nasdaq:DMAC), a clinical-stage biopharmaceutical company focused on development of novel treatments for pre-eclampsia, fetal growth restriction, and acute ischemic stroke. Prior to assuming her position at DiaMedica, Dr. Krop was President of JSK Consulting Services from April 2024 to August 2025. From August 2021 through April 2024, Dr. Krop was the Chief Medical Officer of PureTech Health plc (Nasdaq: PRTC), a clinical stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for people living with psychiatric and neurological conditions. Dr. Krop also served as Chief Medical Officer of Freeline Therapeutics (Nasdaq: FRLN), a clinical stage gene therapy company, from April 2020 to August 2021 and was the Chief Medical Officer and Executive Vice President, Development, with AMAG Pharmaceuticals (Nasdaq: AMAG) from 2015 to 2021. From 2012 to 2015, Dr. Krop served as the Vice President, Clinical Development for Vertex Pharmaceuticals (Nasdaq: VRTX). In addition, Dr. Krop was Vice President, Clinical Development and Regulatory Affairs for Stryker Biotech (NYSE: SYK) from 2006 to 2012. Dr. Krop received a B.A. from Brown University and her M.D. from Brown University School of Medicine. She completed her fellowship in the Department of Endocrinology at the Johns Hopkins University School of Medicine, where she was also a Robert Wood Johnson Foundation Clinical Scholar. Our Board believes that Dr. Krop’s extensive experience in successfully designing and executing clinical development programs from early-stage development through FDA approval, and senior leadership roles across clinical development, regulatory affairs, clinical operations, pharmacovigilance, medical affairs and program management during her career in the pharmaceutical and biotechnology industry, as well as her medical background, qualifies her to serve on our Board of Directors.

Timothy E. Morris has served as a member of our Board since August of 2022. Mr. Morris has served as the Chief Operating Officer of Humanetics Corporation, a privately-held advanced clinical-stage specialty pharmaceutical company, since December, 2025 and a venture partner at LongeVC, a venture capital firm dedicated to supporting exceptional early-stage founders in biotech, since June 2025. Mr. Morris is also the founder and Managing Member of Aacolade Pharma, LLC, a boutique advisory firm assisting biotechnology and pharmaceutical companies with their fundraising, business development and governance needs since its launch in 2023. He previously served as the Chief Financial Officer of Opthea, Limited (NASDAQ: OPT, ASX: OPT) from October, 2022 through October, 2023, and was the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. from 2020 to 2022. Mr. Morris was on the Board of Directors at Humanigen from 2016 to 2020, where he was chairman of the audit committee and a member of the compensation committee, and was also on the Board of Univercells, S.A. from 2021 to 2025 where he was chairman of the audit committee and a member of the strategic committee. Mr. Morris also served as the Chief Financial Officer of Iovance Biotherapeutics, Inc. from 2017 to 2020. Mr. Morris has extensive Board experience, currently serving as a board member of DBV Technologies (NASDAQ: DBVT, Euronext: DBV.PA), where he serves as chairman of the audit committee and a member of the pricing committee; and Humanetics Corporation, where he serves as the chair of the audit committee and a member of the compensation committee. Mr. Morris earned a BS in Business, with an emphasis in accounting, from California State University and is a retired Certified Public Accountant. Our Board believes that Mr. Morris’ extensive business development and company oversight experience in the pharmaceutical industry, along with his experience on the boards of public and private companies and strong finance and management background, qualifies him to serve on our Board of Directors.

Marco Taglietti, M.D. has served as a member of our Board since February 2021. Dr. Taglietti is currently the Chief Executive Officer of NanoNewron, a pioneering biotechnology company developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to treat Alzheimer’s and other central nervous system (CNS) neurodegenerative diseases. Dr. Taglietti previously served as Director, President and Chief Executive Officer of Scynexis Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistance infections, from 2015 until his retirement from Scynexis at the end of 2022. Prior to joining Scynexis, Dr. Taglietti held various executive positions with Forest Laboratories (now Abbvie (NYSE: ABBV) from 2007 until 2014, including President, Forest Research Institute, Chief Medical Officer and Executive Corporate Vice President, Research & Development. Dr. Taglietti was also the Senior Vice President, Head of Global Research and Development for Stiefel Laboratories, Inc. (now a GlaxoSmithKline company) from 2004 until 2007 and served in a number of executive positions from 1992 to 2004 with Schering-Plough Research Institute, including Vice President, Clinical Research Anti-Infectives, CNS, Dermatology and Endocrinology. From 1987 until 1992, Dr. Taglietti served in a number of executive positions with Marion Merrel Dow Research Institute, including as the European Product Team Leader – Anti-Infectives. Dr. Taglietti previously served on the boards of directors of Delcath (NASDAQ:DCTH) from 2014 to 2021 and NephroGenex (NASDAQ:NRX) from 2014 to 2017. Dr. Taglietti also served as a director of Stiefel International, Ltd., a private company, from 2004 to 2007 and a director of TransCelerate BioPharma, a non-profit pharma coalition dedicated to streamlining and accelerating the research and development of innovative new therapies, from 2013 to 2014. From 2011 to 2023, Dr. Taglietti served on the board of directors of BioNJ, a life sciences trade association in New Jersey. In addition, Dr. Taglietti served on the board of directors of HINJ, Health Institute of New Jersey, a trade association for the leading research-based biopharmaceutical and medical technology companies in New Jersey, from 2011 to 2014, and is currently on the board of directors of Orchestra of St. Luke, a New York City based orchestra. Dr. Taglietti received his Degree in Medicine from the University of Pavia, Italy. Our board believes that Dr. Taglietti’s extensive senior experience in the pharmaceutical and biotechnology industry, experience on the boards of both public and private companies, as well as his medical background, qualifies him to serve on our Board of Directors.